Evidence map›Paper›PMID 42070230›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Viscous DES-AAV-Foxo1 Delivery System With High Transfection Efficiency for the Treatment of Corneal Endothelial Dysfunction by Restoring Mitochondria-ER Contacts.

Hongran Zhao, Xiaoyu Li, Hongwei Wang, Zongyi Li, Qun Wang, Yangyang Zhang, Xu Jing, Xia Qi, Qingjun Zhou, Shengqian Dou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hongran ZhaoEye Institute of Shandong First Medical University, Qingdao, China.
Xiaoyu LiEye Institute of Shandong First Medical University, Qingdao, China.
Hongwei WangEye Institute of Shandong First Medical University, Qingdao, China.ORCID https://orcid.org/0000-0002-2466-822X
Zongyi LiEye Institute of Shandong First Medical University, Qingdao, China.
Qun WangEye Institute of Shandong First Medical University, Qingdao, China.
Yangyang ZhangEye Institute of Shandong First Medical University, Qingdao, China.
Xu JingDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Xia QiEye Institute of Shandong First Medical University, Qingdao, China.
Qingjun ZhouEye Institute of Shandong First Medical University, Qingdao, China.
Shengqian DouEye Institute of Shandong First Medical University, Qingdao, China.
Lixin XieEye Institute of Shandong First Medical University, Qingdao, China.

Funding

Joint Innovation Team for Clinical & Basic Research 202405National Natural Science Foundation of China 82571177Shandong Provincial Key Research and Development Program 2021ZDSYS14Taishan Scholar Program 202306390Youth Innovation Team Program in Shandong Province 2022KJ186
6 · The paper itself

Abstract

Corneal endothelial dysfunction is a major cause of global blindness, with an estimated 12.7 million patients awaiting corneal transplantation, and the severe shortage of donor grafts underscores the urgent need for non-surgical therapies. Gene therapy offers a promising alternative, but is hindered by the limitations in existing delivery systems and the scarcity of validated molecular targets capable of reversing core pathophysiology. To address this, we first employed multi-omics analysis and identified FOXO1 as a central and under-explored therapeutic target for corneal endothelial dysfunction. In vivo FOXO1 overexpression effectively improved corneal endothelial function by preserving mitochondria-associated endoplasmic reticulum membrane integrity and mitochondrial Ca

Indexed as

DependovirusEndoplasmic ReticulumEndothelium, CornealForkhead Box Protein O1Fuchs' Endothelial DystrophyGenetic TherapyMitochondriaTransfectionAnimalsDisease Models, AnimalGene Therapy AgentsHumansMaleMiceForkhead Box Protein O1corneal endothelial dysfunctiondeep eutectic solvent (DES)FOXO1gene deliverymitochondria‐associated endoplasmic reticulum membranes (MAMs)

Identifiers

PMID42070230
PMCPMC13335468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.